{
    "clinical_study": {
        "@rank": "149696", 
        "acronym": "PropTCI/2012", 
        "arm_group": [
            {
                "arm_group_label": "propofol", 
                "arm_group_type": "Experimental", 
                "description": "Patients in Group Propofol(n=70) were seated with propofol target concentration 1.2-1.6 \u00b5g/ml. Patients in both groups undergoing CS received also iv fentanyl (1\u03bcg/Kg) for pain control."
            }, 
            {
                "arm_group_label": "midazolam", 
                "arm_group_type": "Active Comparator", 
                "description": "Control Group: patients in Group midazolam (n=70) were sedated with midazolam 0.04 mg/kg  if aged< 70 - 0.03 mg/kg  if aged> 70. Patients in both groups undergoing CS received also iv fentanyl (1\u03bcg/Kg) for pain control."
            }
        ], 
        "brief_summary": {
            "textblock": "Many studies address safety and effectiveness of non-anesthesiologist propofol sedation\n      (NAPS) for GI endoscopy. Target Controlled Infusion (TCI) is a sophisticated tool for\n      providing optimal sedation regimen and avoiding under or oversedation.\n\n      This randomized double blind controlled study compares standard moderate sedation level of\n      sedation (group S) during upper endoscopy (EGD) and colonoscopy (CS) versus propofol NAPS\n      (group P)."
        }, 
        "brief_title": "Propofol TCI Administered by Gastroenterologists During Endoscopy: a Randomized Double Blind Controlled Study", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Propofol", 
            "Target Controlled Infusion", 
            "Moderate Sedation", 
            "Gastrointestinal Endoscopy"
        ], 
        "detailed_description": {
            "textblock": "70 CS and 70 EGD ASA I-II patients were studied. In group S (n=70) we administered fentanyl\n      (1\u03bcg/kg) + midazolam (0.04-0.03 mg/kg) for CS and midazolam (0.04-0.03 mg/kg) for EGDS and\n      in group P (n=70) fentanyl 1\u00b5g/Kg + propofol TCI 1.2-1.6 \u03bcg/ml for CS and propofol TCI\n      1.2-1.6 \u03bcg/ml for EGD. Vital parameters and Observer's Assessment of Alertness and Sedation\n      Scale (OAA/S) were monitored throughout the study. Endoscopist's and patient's satisfactions\n      were measured after procedure and 24-72 h later by visual analog scale (VAS)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age >18 yrs\n\n          -  ASA (American Society of Anesthesiologists risk class III-IV)I-II\n\n          -  patients undergoing to gastroscopy or colonoscopy\n\n        Exclusion Criteria:\n\n          -  significant systemic disease (American Society of Anesthesiologists risk class\n             III-IV)\n\n          -  history of allergic reactions to any of the study drugs\n\n          -  chronic use of opioid analgesics\n\n          -  psychiatric disorder\n\n          -  pregnancy\n\n          -  difficult airways (Mallampati score >2)\n\n          -  age <18 yrs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01941888", 
            "org_study_id": "PropTCI2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "propofol", 
                "intervention_name": "Propofol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "midazolam", 
                "intervention_name": "Midazolam", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "propofol", 
                "intervention_name": "Target Controlled Infusion", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Midazolam", 
                "Propofol"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 10, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Milan", 
                        "country": "Italy"
                    }, 
                    "name": "San Raffaele Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milan", 
                        "country": "Italy", 
                        "zip": "20132"
                    }, 
                    "name": "San Raffaele Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase IV Study of Propofol TCI (Target Controlled Infusion)Administered by Gastroenterologists During Endoscopy in Moderate Sedation: a Randomized Double Blind Controlled Study", 
        "overall_official": [
            {
                "affiliation": "San Raffele Hospital", 
                "last_name": "Massimo Agostoni, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "San Raffaele Hospital", 
                "last_name": "Lorella Fanti, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "San Raffaele Hospital", 
                "last_name": "Marco Gemma, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Italy: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Endoscopist's satisfaction was measured after endoscopic procedures by visual analog scale (VAS 0-100).", 
                "measure": "Endoscopist's VAS (Visual Analog Scale) satisfaction about propofol TCI moderate sedation", 
                "safety_issue": "No", 
                "time_frame": "one day"
            }, 
            {
                "description": "Patient's satisfactions were measured after endoscopic procedures and 24-48 hours later by visual analog scale (VAS 0-100).", 
                "measure": "Patient's VAS (Visual Analog Scale) satisfactions about propofol TCI moderate sedation", 
                "safety_issue": "No", 
                "time_frame": "one day"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01941888"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ospedale San Raffaele", 
            "investigator_full_name": "Agostoni Massimo", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To compare safety (number of partecipants with adverse events) of propofol TCI versus midazolam iv boluses during upper endoscopy (EGD) and colonoscopy (CS). Both sedation regimens were administered by endoscopists.", 
                "measure": "Safety (number of partecipants with adverse events) of propofol TCI moderate sedation", 
                "safety_issue": "Yes", 
                "time_frame": "one day"
            }, 
            {
                "description": "To compare time to dischargeability (minutes to reach Modified Aldrete score \u2265 18) of patients in group standard versus propofol TCI group\nsafety (number of partecipants with adverse events) of propofol TCI versus midazolam iv boluses during upper endoscopy (EGD) and colonoscopy (CS). Both sedation regimens were administered by endoscopists.", 
                "measure": "Time to dischargeability (minutes to reach Modified Aldrete score \u2265 18) of patients", 
                "safety_issue": "Yes", 
                "time_frame": "one day"
            }
        ], 
        "source": "Ospedale San Raffaele", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ospedale San Raffaele", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}